bpc-157 immunogenicity concerns fda The FDA's Briefing Document Says Less Than It Sounds Like ahk-cu 5-Amino-1MQ Research Compound | size:10ml

bpc-157 immunogenicity concerns fda The FDA's Briefing Document Says Less Than It Sounds Like ahk-cu 5-Amino-1MQ Research Compound | size:10ml

5-Amino-1MQ Research Compound | Laboratory Research Material

Specific volumes, target concentrations, and dose calculations cited in non-clinical or informal sources are not derived from authoritative data and may be inaccurate, unsafe, or based on products of unknown quality and purity

ahk-cu

size:10ml

Dose selection by research model Representative protocol doses by endpoint: Achilles tendon transection (rat): 10 µg/kg IP daily for 14-21 days MCL transection (rat): 10 µg/kg IP daily for 30 days Muscle crush injury (rat): 10 µg/kg IP or IM daily for 7-14 days Gastric ulcer (rat): doses from 10 ng/kg through 10 µg/kg evaluated